Showing posts with label chemicals. Show all posts
Showing posts with label chemicals. Show all posts
Tuesday, 31 October 2017
"DS Smith & Croda - UK companies doing the business"
I wrote a piece titled...
...which was uploaded just now to the ShareProphets website. A link to the piece (free sign-up) is here.
Friday, 27 March 2015
"Dow Chemical: another piece of impressive deal making"
My latest post as a Yahoo Finance Contributor titled "Dow Chemical: another piece of impressive deal making" can be found here.

Thursday, 23 October 2014
Dow Chemical - warming up to the story
At the last Dow Chemical quarterly disclosure (before today's) in July I observed here that:
'The question for Dow Chemical...is the extent of the discounting of the next stage opportunities/investments/products. Still a x15s EV/ebit multiple does factor a lot of this - and the above unbundling - in.'
Since then the fall in the share price (from early US$50s to mid US$47s as I write) has started to bring a little bit of relief in the valuation...
...and the asset unbundling story continues apace (assisted by some continued activist interest).
To put US$6bn into context, this would be 8%+ of the company's EV. Not too shabby if achieved.
Now of course this strategy has been in place for a number of quarters now, so what is either new or worth noting? Well, pricing was sequentially year-on-year better...
...and this helped drive ebitda margins across the board:
'The question for Dow Chemical...is the extent of the discounting of the next stage opportunities/investments/products. Still a x15s EV/ebit multiple does factor a lot of this - and the above unbundling - in.'
Since then the fall in the share price (from early US$50s to mid US$47s as I write) has started to bring a little bit of relief in the valuation...
To put US$6bn into context, this would be 8%+ of the company's EV. Not too shabby if achieved.
Now of course this strategy has been in place for a number of quarters now, so what is either new or worth noting? Well, pricing was sequentially year-on-year better...
...and this helped drive ebitda margins across the board:
I also liked the commentary/progression in the some of the company's more commoditised markets such as polyethylene. Rising prices and operating rates do not always go hand in hand but so far this is working out well.
And then from a catalyst perspective the investor day in just over three weeks seems potentially worthy. Certainly I like the choice of subjects.
Now Dow Chemical is still not ultra-cheap but trading now more in the x12s EV/ebit prospectively with the aforementioned value realisation / upcoming investor communication I am warming up to the story more. I also note from the chart above that there appears to be some support in the US$44s.
Monday, 21 April 2014
Akzo Nobel - good pricing power but, but...
The Dutch listed coatings company Akzo Nobel summarised corporate realities in Europe fairly well last week when, in their Q1 earnings summary, they noted falling revenues due to company influence and flattish profitability but an improvement in pricing power and additionally an improvement too in the cash flow characteristics of the business. It is that sort of world at the moment: improvements and dullness/disappointments in equal measure.
I have talked before about my preference for strong pricing power and for me Akzo Nobel gets a tick in the box for its recent aggregate pricing move...
...which was apparent in all three of the company's major divisions. That's quite impressive:
This should be the norm for a business with strong market positions...
...and an increasing emerging market focus.
Note though the continued importance of mainstream Europe for the business. Given the company's heritage this is no surprise and clearly this means that the company's focus is just as much shrinking / improving efficiency in the European business as searching for emerging market growth.
This makes the comment about the 2015 targets hugely important for the company. If you assume an improvement to the 9% operating margin target that's around a Euro1.2bn potential operating profit and the company on a prospective x12 EV/ebit FY15e rating.
That is ok but not stunning and reflects the need to be a believer in an economic cycle improvement to get really excited about this share. The dividend yield of 2.7% is some compensation but I note some variability with cash flow. The company should generate sufficient free cash to cover this but it is not - with all the restructuring spend etc - a cash flow machine yet in my view.
Back in early February I talked about 'the mid Euro40s' as a more appropriate share purchase level. Given the improvement in underlying pricing power I am going to evolve that to 'sub Euro50'. In hindsight that Euro60 resistance level seen earlier this year was a good tactical shorting opportunity.
I have talked before about my preference for strong pricing power and for me Akzo Nobel gets a tick in the box for its recent aggregate pricing move...
...which was apparent in all three of the company's major divisions. That's quite impressive:
This should be the norm for a business with strong market positions...
...and an increasing emerging market focus.
Note though the continued importance of mainstream Europe for the business. Given the company's heritage this is no surprise and clearly this means that the company's focus is just as much shrinking / improving efficiency in the European business as searching for emerging market growth.
This makes the comment about the 2015 targets hugely important for the company. If you assume an improvement to the 9% operating margin target that's around a Euro1.2bn potential operating profit and the company on a prospective x12 EV/ebit FY15e rating.
That is ok but not stunning and reflects the need to be a believer in an economic cycle improvement to get really excited about this share. The dividend yield of 2.7% is some compensation but I note some variability with cash flow. The company should generate sufficient free cash to cover this but it is not - with all the restructuring spend etc - a cash flow machine yet in my view.
Back in early February I talked about 'the mid Euro40s' as a more appropriate share purchase level. Given the improvement in underlying pricing power I am going to evolve that to 'sub Euro50'. In hindsight that Euro60 resistance level seen earlier this year was a good tactical shorting opportunity.
Monday, 3 March 2014
Dow Chemical - in a top-slicing/profit-taking zone?
Dow Chemical has performed extremely strongly over the last year.
So why is this? First the company has had a plan to sharpen up its own range of operations via the announced sale and turnaround focus of some of the historic core non-speciality chemicals businesses.
So what price today for combination of realities and opportunities? Currently the stock is on x14 forward EV/ebit. For a more specialist-focused chemicals stock - even one with on-going restructurings and activist sniping this is full. Free cash flow is around 6% (half paid out as a dividend) and net debt is x1.7 ebitda which is ok (albeit potentially moved around by the big buy back announced above).
After such a great run this feels full. Even assuming the company noted target of achieving a US$10bn ebitda, this would still suggest an EV/ebit of x10.
Dow Chemical has been a strong share but it feels in a top-slicing/profit-taking zone to me. Have a fresh look for new capital much nearer US$40.
So why is this? First the company has had a plan to sharpen up its own range of operations via the announced sale and turnaround focus of some of the historic core non-speciality chemicals businesses.
In a recent presentation the company put some detail on this indicating that (by market cap) around 10% of the company was going to be impacted:
Second, the company has attracted some activist interest. This quote is from an article published last month concerning the well-known activist Dan Loeb
'Loeb is calling for a spinoff of Dow’s petrochemicals business, which in his eyes would improve the company’s profitability. He’s also asking DOW to consider a big share buyback that would in essence help to offset a convertible bond deal whereby Berkshire Hathaway (BRK.B) and the Kuwait Investment Authority will get issued a large amount of stock'.
Dow Chemical have told Dan Loeb that they are not interested in his suggestions but - as always - there is no smoke without fire.
Third, AgroSciences remains a growth area (need to improve yield globally due to a growing population/changing diets etc) and Dow's businesses have continued to perform well...
...with a good pipeline of new products upcoming too:
Recent operating performance has improved, although clearly a good amount of this is due to the broader US economy. The above rationalisation, spin-off pressure and continuing AgroSciences performance offer further scope. In January, reflecting this, the company's 2014 was tripled in size to US$4.5bn (or around 8% of the market cap).
Or was the share buyback for another reason? This is from a Seeking Alpha contributor who makes an interesting point about the aforementioned convertible:
'In 2009 Dow issued a total of $4 billion in convertible
preferred shares to Berkshire Hathaway (BRK.A, BRK.B) and Saudi Aramco (SA) in
order to complete their acquisition of Rohm & Haas. These shares pay a
preferred dividend of 8.5% and have a strike price of $41.32. It is unlikely
that Berkshire or SA will opt to convert these shares because of the hefty
dividend and the value of the call options. However, this large dividend is
burdensome to Dow, and Dow can force conversion if the common stock price
exceeds $53.72 per share for any 20 trading days in a consecutive 30-day
window'
After such a great run this feels full. Even assuming the company noted target of achieving a US$10bn ebitda, this would still suggest an EV/ebit of x10.
Dow Chemical has been a strong share but it feels in a top-slicing/profit-taking zone to me. Have a fresh look for new capital much nearer US$40.
Tuesday, 25 February 2014
BASF's interesting Euro call
BASF quarterly results always have some interesting insights as you would expect from 'the world's largest chemicals company'. When I last wrote about the company in November I noted that:
'BASF are lucky that they have an agricultural unit as the core chemicals/performance products divisions are being hit by poor pricing and the high exchange rate head-on.
Will it get better? Here is the formal outlook from the company:
Some more resistance at Euro75/76 in the shares then? Quite possibly...'
The thrust of my November views still seems to be the case as the key outlook quote from the company's Q4/FY report today was:
'We do not expect strong tailwinds this year either...For the global chemical industry, the company anticipates growth rates comparable with the previous year’s level and forecasts somewhat higher growth in key customer industries such as the transportation, consumer goods and electronics industries'
On one aspect I was wrong though and that was the share price. I expected more resistance in the share price at the Euro75-76 level but the shares blasted through that and today sit at just over Euro82. Just like the German DAX Index, BASF shares have had a good last three years and at x14 earnings and a near 3.5% dividend yield are not - at face value - very highly valued.
Momentum though is a funny thing. I noted that BASF's dull but positive guidance was based on a number of criteria including sequentially better global growth in 2014 (2.8% versus 2.3%e for FY13) and this comment on the Euro/US Dollar exchange rate:
Both are interesting calls. On the former I could not help but notice the split of the German economic growth numbers out earlier today (0.4% in Q4 year-on-year) in a Reuters report (with my emphasis added):
'A detailed breakdown showed domestic demand subtracted 0.7 percentage points from growth while foreign trade, which had been weak for much of 2013, added 1.1 percentage points to GDP.
The statistics office said the domestic economy sent "mixed signals". Capital investment picked up significantly, big inventory reductions slammed the brakes on growth and public expenditure was stagnant while private consumption dipped. But economists expect domestic demand to gain momentum this year and Berlin is relying on it to drive a predicted 1.8% expansion while foreign trade is expected to dampen growth'
That sounds a bit...messy whilst the exchange rate is nearly 6% above where BASF anticipate seeing it on average during 2014.
'BASF are lucky that they have an agricultural unit as the core chemicals/performance products divisions are being hit by poor pricing and the high exchange rate head-on.
Will it get better? Here is the formal outlook from the company:
Some more resistance at Euro75/76 in the shares then? Quite possibly...'
The thrust of my November views still seems to be the case as the key outlook quote from the company's Q4/FY report today was:
'We do not expect strong tailwinds this year either...For the global chemical industry, the company anticipates growth rates comparable with the previous year’s level and forecasts somewhat higher growth in key customer industries such as the transportation, consumer goods and electronics industries'
On one aspect I was wrong though and that was the share price. I expected more resistance in the share price at the Euro75-76 level but the shares blasted through that and today sit at just over Euro82. Just like the German DAX Index, BASF shares have had a good last three years and at x14 earnings and a near 3.5% dividend yield are not - at face value - very highly valued.
Momentum though is a funny thing. I noted that BASF's dull but positive guidance was based on a number of criteria including sequentially better global growth in 2014 (2.8% versus 2.3%e for FY13) and this comment on the Euro/US Dollar exchange rate:
'An average euro/dollar exchange rate of $1.30 per euro'
Both are interesting calls. On the former I could not help but notice the split of the German economic growth numbers out earlier today (0.4% in Q4 year-on-year) in a Reuters report (with my emphasis added):
'A detailed breakdown showed domestic demand subtracted 0.7 percentage points from growth while foreign trade, which had been weak for much of 2013, added 1.1 percentage points to GDP.
The statistics office said the domestic economy sent "mixed signals". Capital investment picked up significantly, big inventory reductions slammed the brakes on growth and public expenditure was stagnant while private consumption dipped. But economists expect domestic demand to gain momentum this year and Berlin is relying on it to drive a predicted 1.8% expansion while foreign trade is expected to dampen growth'
That sounds a bit...messy whilst the exchange rate is nearly 6% above where BASF anticipate seeing it on average during 2014.
It seems strange to be moving towards a conclusion that a prospectively weak Euro, weak DAX and weak BASF share price is a conclusion that I am moving towards given that the latter two are export-centric (and so should benefit from a weaker Euro) but that is what I am moving towards...even if Mr Draghi has some bold ideas to discuss at the next ECB meeting in early March.
Monday, 16 December 2013
Ejected from the FTSE100...should it be injected into your portfolio?
As this article notes, last week:
'...the latest quarterly review of the FTSE 100 has...been published. The review sees Vedanta Resources and Croda International drop out of the UK’s top index, and Royal Mail and Ashtead join the blue-chip elite...the changes take effect from the start of trading on Monday 23 December'
Whenever I hear about index changes I think opportunity...specifically for those companies being ejected. Removal from an index can induce an opportunity as index trackers sell.
I have talked about Vedanta before (take a look at this link, for example). The shares have been hit hard both by the FTSE 100 (anticipated and then confirmed) ejection plus rotation away from the mining sector and fears about Indian economic growth levels (where the company has much of its revenue/profit generating divisions). I noted in the linked article above that the share was sub book value below £10 (and exhibited historic technical support at that level) only for the share to fall through this level...and £9...and £8 as shown below.
I have been building my position at each of the above levels, moving from a starter position to more of a medium-sized one at prevailing. In my opinion the now confirmed ejection from the FTSE 100 index has helped create an opportunity for 2014.
But what about Croda? Here is how the company describes themselves on their corporate website:
'Croda is a world leader in natural based speciality chemicals which are sold to virtually every type of industry. The company has approximately 3400 employees, working in 34 countries.
Activities can be broadly classified into three sectors:
Consumer Care which consists of global businesses in personal care, health care and crop care – all markets with an increasing need for innovation and sustainable ingredients.
Performance Technologies which comprises home care, additives for polymers, coatings and polymers, lubricant additives, and geo technologies.
Industrial Chemicals which consists of base oleochemicals and co-products.
In addition, the group has an Technology Investment Group function which identifies and integrates new technology into Croda’s global business structure'
This sounds...quite difficult to pin down precisely (e.g. 'sold to virtually every type of industry'). Fortunately there was a capital markets day presentation in November (link here) to help provide insight.
What I immediately like about the company is its global (turnover 35% in the emerging markets and 26% in North America), mega-trend focus and attempts to build barriers-to-entry as shown below.
The difference though with Croda concerning building product with barriers-to-entry is the size of the average product. I thought this was very insightful: 'a 1000 x £1m product company'
And then to augment this position further, the company has continued to acquire complementary companies around the world such as (a majority stake in) Sipo in China and Arizona Chemical.
But that does not answer the question...why the weakness? Well, business conditions in 2013 to-date have been quite as conducive as previous years, as shown below.
Why is this? Well, as noted below, a number of issues came together such as declining emerging market sales and weak European automotive markets. Many companies have complained about sequentially poor emerging market sales and Croda has not been able to buck the trend, although some improvement appears to be occurring (as per the Q3 update), although auto sales are still weak and currency benefits have reduced.
So what we have here is a company where investors had started to extrapolate high single digit growth...and then were surprised when it did not happen. This is why the shares are around one year lows.
Is the model broken though? No. Clearly some risks remain but the positive themes that have underpinned the company's rise over the last few years remain too. Extrapolating the H1 2013 results puts the company today on a just sub x12 EV/ebit rating for FY13e with a 3% yield and a 5%+ free cash flow generation capability. These are multiples that sound like a starter position potential to me.
As noted above, ejection from the FTSE 100 can create opportunities.
'...the latest quarterly review of the FTSE 100 has...been published. The review sees Vedanta Resources and Croda International drop out of the UK’s top index, and Royal Mail and Ashtead join the blue-chip elite...the changes take effect from the start of trading on Monday 23 December'
Whenever I hear about index changes I think opportunity...specifically for those companies being ejected. Removal from an index can induce an opportunity as index trackers sell.
I have talked about Vedanta before (take a look at this link, for example). The shares have been hit hard both by the FTSE 100 (anticipated and then confirmed) ejection plus rotation away from the mining sector and fears about Indian economic growth levels (where the company has much of its revenue/profit generating divisions). I noted in the linked article above that the share was sub book value below £10 (and exhibited historic technical support at that level) only for the share to fall through this level...and £9...and £8 as shown below.
I have been building my position at each of the above levels, moving from a starter position to more of a medium-sized one at prevailing. In my opinion the now confirmed ejection from the FTSE 100 index has helped create an opportunity for 2014.
But what about Croda? Here is how the company describes themselves on their corporate website:
'Croda is a world leader in natural based speciality chemicals which are sold to virtually every type of industry. The company has approximately 3400 employees, working in 34 countries.
Activities can be broadly classified into three sectors:
Consumer Care which consists of global businesses in personal care, health care and crop care – all markets with an increasing need for innovation and sustainable ingredients.
Performance Technologies which comprises home care, additives for polymers, coatings and polymers, lubricant additives, and geo technologies.
Industrial Chemicals which consists of base oleochemicals and co-products.
In addition, the group has an Technology Investment Group function which identifies and integrates new technology into Croda’s global business structure'
This sounds...quite difficult to pin down precisely (e.g. 'sold to virtually every type of industry'). Fortunately there was a capital markets day presentation in November (link here) to help provide insight.
What I immediately like about the company is its global (turnover 35% in the emerging markets and 26% in North America), mega-trend focus and attempts to build barriers-to-entry as shown below.
The difference though with Croda concerning building product with barriers-to-entry is the size of the average product. I thought this was very insightful: 'a 1000 x £1m product company'
Then bringing together innovation and globalisation, I thought the following two charts made some sense too, in the mechanics of 'delivering innovation'...
...and then better leveraging local/regional insights across their global operations/client base:
And then to augment this position further, the company has continued to acquire complementary companies around the world such as (a majority stake in) Sipo in China and Arizona Chemical.
Fortunately the company retains a strong balance sheet with net debt (at the H1 stage) of £222m debt or just x0.7 net debt:ebitda.
So combining innovation and a global and positive thematic orientation has led to some solid recent results, as shown below. High single digit annualised growth will placate most investors:
So why is the share falling out of the FTSE 100 then? Well, to state the obvious, the share is kicking around one year lows and it is this weakness which has induced the decision: But that does not answer the question...why the weakness? Well, business conditions in 2013 to-date have been quite as conducive as previous years, as shown below.
Why is this? Well, as noted below, a number of issues came together such as declining emerging market sales and weak European automotive markets. Many companies have complained about sequentially poor emerging market sales and Croda has not been able to buck the trend, although some improvement appears to be occurring (as per the Q3 update), although auto sales are still weak and currency benefits have reduced.
So what we have here is a company where investors had started to extrapolate high single digit growth...and then were surprised when it did not happen. This is why the shares are around one year lows.
Is the model broken though? No. Clearly some risks remain but the positive themes that have underpinned the company's rise over the last few years remain too. Extrapolating the H1 2013 results puts the company today on a just sub x12 EV/ebit rating for FY13e with a 3% yield and a 5%+ free cash flow generation capability. These are multiples that sound like a starter position potential to me.
As noted above, ejection from the FTSE 100 can create opportunities.
Tuesday, 22 October 2013
A few company presentation charts out on Tuesday (DuPont, Harley Davidson, United Technologies)
A selection of charts from presentations given by US corporates today.
DuPont -
Shares in the diversified chemical company appear to have formed a triple top at US$60. I was not blown away by the numbers though, as indicated by this chart, showing an apparent preference for volume over prices in Q3:
In contrast to DuPont above, Harley Davidson exhibited good pricing power, to the tune of over US$1,200 per motorcycle over the last year. Impressive.
United Technologies - with interests ranging from lifts (Otis), to aircraft engines (Pratt & Whitney) and to a variety of military aerospace is always a bell-weather. Here are the two charts I thought were most interesting from their presentation:
The growth is in China and commercial aerospace...and unsurprisingly not in military aerospace and perhaps surprisingly in Asia ex China:
I thought this 2014 outlook statement was a little different. Not often you see the emerging markets as an overt positive. Correctly, in my view too, the Eurozone is ranked below other regional zones. Note too that they prefer the aftermarket to the original equipment market in commercial aerospace, and whilst being positive about the US economic recovery, they are negative about Department of Defence spending.
DuPont -
Shares in the diversified chemical company appear to have formed a triple top at US$60. I was not blown away by the numbers though, as indicated by this chart, showing an apparent preference for volume over prices in Q3:
In contrast to DuPont above, Harley Davidson exhibited good pricing power, to the tune of over US$1,200 per motorcycle over the last year. Impressive.
United Technologies - with interests ranging from lifts (Otis), to aircraft engines (Pratt & Whitney) and to a variety of military aerospace is always a bell-weather. Here are the two charts I thought were most interesting from their presentation:
The growth is in China and commercial aerospace...and unsurprisingly not in military aerospace and perhaps surprisingly in Asia ex China:
I thought this 2014 outlook statement was a little different. Not often you see the emerging markets as an overt positive. Correctly, in my view too, the Eurozone is ranked below other regional zones. Note too that they prefer the aftermarket to the original equipment market in commercial aerospace, and whilst being positive about the US economic recovery, they are negative about Department of Defence spending.
Monday, 21 October 2013
Industrial facing - Europe. The case of Akzo Nobel
Investor sentiment is high and a number of global markets are kicking around all-time highs. Industrial stocks always give a good view and insight into global progress. So what have some leading global industrial names said over the last couple of business days?
Let's start in Europe. Industrials in Europe have not had the best start to the earnings season - we have already noted the disappointing numbers from SKF and Konecranes (link here and here). However, in contrast to this, one of the strongest shares in Europe today is Akzo Nobel (chemicals/coatings). Are they saying anything particularly different or is this just sentiment-driven?
Akzo Nobel is not growing via rising margins and improved price-mix, constant currency operating income is up strongly.
I think this was probably the most interesting chart in their presentation pack: easy comps from last year and an improvement in volumes/price-mix. Not bad at all.
Akzo Nobel has some big picture positive attributes as the global leader in decorative paints/coatings and with getting on for a third of sales in Asia. Their 2015 plan to improve returns adds hope too.
As noted below, the share is close to one-year highs and, in a way, I see the company at the forefront of the perception positivity in the world today. At c. x13 EV/ebit FY13e, the share is more than fully valued as a cyclical today, but clearly baked into this are the hoped-for improvements in 2014-15.
Akzo Nobel is an ok turnaround story but much depends on a continuation of the improvement...and perception towards that. Look at the chart below of the last two years. Akzo Nobel and the S&P500 (as a proxy for global markets) are, from A-to-B, show very similar performance. Akzo Nobel out and under performs broader indices at points of (respectively) good and bad market sentiment.
Sentiment feels too high at the moment, so wait/pause.
Remember how everyone loves Europe at the moment as per the latest Bank of America Fund Manager Survey:
'Europe has been able to avoid the downward shift in global sentiment with equity allocations reaching a six-year high. A net 46 percent of asset allocators are overweight European equities, up from a net 36 percent September and representing the highest reading since 2007'.
Let's start in Europe. Industrials in Europe have not had the best start to the earnings season - we have already noted the disappointing numbers from SKF and Konecranes (link here and here). However, in contrast to this, one of the strongest shares in Europe today is Akzo Nobel (chemicals/coatings). Are they saying anything particularly different or is this just sentiment-driven?
Akzo Nobel is not growing via rising margins and improved price-mix, constant currency operating income is up strongly.
I think this was probably the most interesting chart in their presentation pack: easy comps from last year and an improvement in volumes/price-mix. Not bad at all.
Akzo Nobel has some big picture positive attributes as the global leader in decorative paints/coatings and with getting on for a third of sales in Asia. Their 2015 plan to improve returns adds hope too.
As noted below, the share is close to one-year highs and, in a way, I see the company at the forefront of the perception positivity in the world today. At c. x13 EV/ebit FY13e, the share is more than fully valued as a cyclical today, but clearly baked into this are the hoped-for improvements in 2014-15.
Akzo Nobel is an ok turnaround story but much depends on a continuation of the improvement...and perception towards that. Look at the chart below of the last two years. Akzo Nobel and the S&P500 (as a proxy for global markets) are, from A-to-B, show very similar performance. Akzo Nobel out and under performs broader indices at points of (respectively) good and bad market sentiment.
Sentiment feels too high at the moment, so wait/pause.
Remember how everyone loves Europe at the moment as per the latest Bank of America Fund Manager Survey:
'Europe has been able to avoid the downward shift in global sentiment with equity allocations reaching a six-year high. A net 46 percent of asset allocators are overweight European equities, up from a net 36 percent September and representing the highest reading since 2007'.
Subscribe to:
Posts (Atom)






































